Latest News and Press Releases
Want to stay updated on the latest news?
-
Heidelberg, Germany, February 27, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system,...
-
Heidelberg, Germany, February 21, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system,...
-
Heidelberg, Germany, January 4, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system,...
-
- Company to Pursue Registrational Pathway for Lead Agent AFM13 Monotherapy in Patients with Peripheral T Cell Lymphoma with Potential for Accelerated Approval - - Clinical Studies for AFM13...
-
- Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate of AFM13 in Combination with Keytruda®...
-
Heidelberg, Germany, November 28, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, November 8, 2018 -...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Established strategic collaboration...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, November 1, 2018 -...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Heidelberg, Germany, October 31, 2018 - Affimed...